What is the marketed drugs overview of the gastroparesis therapeutics market?
February 3, 2023 ⚊ 1 Min read ⚊ Views 77 ⚊ HEALTH
Prokinetic agents are the cornerstone of pharmacotherapy for gastroparesis. Metoclopramide (Reglan and Gimoti), a dopamine D2 receptor antagonist, has both prokinetic and antiemetic properties. It is the only medication specifically approved by the FDA for the treatment of gastroparesis. It increases the contraction amplitude of esophageal fundic and antral musculature. Since it crosses the blood-brain barrier, the use of metoclopramide is often limited by its undesired side effects. These range from mild sedation and agitation to extrapyramidal effects like involuntary movements.
Tags: gastroparesis-competitive
